#United States #New York #Gross Law Firm #Regeneron Pharmaceuticals #Eylea

Important Notice for Regeneron Pharmaceuticals Shareholders

The Gross Law Firm has recently issued a critical reminder for shareholders of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) regarding a significant upcoming deadline in a class action lawsuit. Shareholders who purchased shares during a specific class period are urged to take action promptly.

Class Period Details

The class period in focus runs from November 2, 2023, to October 30, 2024. This timeframe is crucial for any shareholder who may have been affected by allegations against the company.

The lawsuit outlines several serious allegations against Regeneron that merit the attention of its investors. These allegations claim that the company made materially false or misleading statements, or failed to disclose vital information that may impact shareholders' positions and understanding of their investments in Regeneron.

Allegations Against Regeneron

The primary claims include:
1. Regeneron allegedly paid credit card fees to distributors contingent upon a promise that those distributors would not impose higher charges on customers when using credit cards to purchase Eylea, one of the company's main products.
2. These actions resulted in subsidized pricing for customers, which in turn afforded Regeneron a competitive advantage in the marketplace, particularly affecting the pricing dynamics of retinal practices that utilize anti-VEGF medications.
3. Consequently, the company is accused of inflating reported sales figures of Eylea, misleading both consumers and regulators, violating federal laws in the process.
4. Specifically, the complaint highlights that Regeneron’s failure to accurately report credit card fee payments as price concessions misled federal agencies regarding reported Average Selling Prices (ASP) for health care pricing.

Such misrepresentations have serious ramifications not just for the company but also for its investors, significantly eroding trust and resulting in potential financial losses that shareholders might be looking to recover.

Actions for Shareholders

To safeguard their rights, shareholders who acquired REGN shares during the stated period are encouraged to register for participation in this class-action lawsuit promptly. The crucial deadline to be recognized as lead plaintiff is March 10, 2025. Registering does not obligate shareholders to participate but offers them an opportunity to voice their concerns and potentially seek recoveries for losses incurred due to alleged misleading practices.

Shareholders can complete their registration and learn more about the case through the Gross Law Firm's dedicated portal. Once registered, investors will also gain access to a portfolio monitoring software that will keep them updated on the case's developments, ensuring they remain informed throughout the entire process.

Why Choose The Gross Law Firm?

The Gross Law Firm is well-known across the nation for its dedication to protecting investors’ rights. They aim to hold companies accountable for deceitful actions that lead to losses and defend against unfair business practices. Their commitment to corporate accountability ensures that investors have a voice in the legal system when they have been wronged.

In conclusion, shareholders of Regeneron Pharmaceuticals should take immediate action and consider their next steps in light of these allegations and the approaching deadline. Being proactive could mean the difference between recovery and continued loss for many involved in this ongoing lawsuit. For further inquiries, interested parties can reach out to the Gross Law Firm directly.

Contact Information:
The Gross Law Firm
15 West 38th Street, 12th Floor
New York, NY, 10018
Phone: (646) 453-8903
Email: [email protected]